{
    "nctId": "NCT00068757",
    "briefTitle": "Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",
    "officialTitle": "Phase I Study of Lonafarnib (SCH66336) in Combination With Herceptin Plus Paclitaxel in HER 2 NEU Overexpressing Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 23,
    "primaryOutcomeMeasure": "Dose-limiting toxicity and maximum tolerated dose as measured by CTC v 2.0",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Stage IIIB, IIIC, or IV\n* HER2/neu overexpression\n\n  * 3+ by immunohistochemistry\n\n    * 2+ allowed if positive fluorescent in situ hybridization\n* Disease meets the following treatment criteria:\n\n  * Paclitaxel/trastuzumab (Herceptin\u00ae) may be appropriate therapy\n  * Anthracycline therapy is not a suitable approach\n* No clinical signs of CNS involvement\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2 OR\n* WHO 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Hemoglobin at least 10.0 g/dL (6.2 mmol/L)\n\nHepatic\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase less than 2.5 times ULN (5 times ULN if liver metastases are present)\n* AST and ALT less than 2.5 times ULN (5 times ULN if liver metastases are present)\n\nRenal\n\n* Creatinine clearance at least 40 mL/min\n\nCardiovascular\n\n* Cardiac ejection fraction normal by MUGA\n* QTc interval no greater than 440 msec\n* No cardiac dysfunction\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for up to 3 months after study participation\n* No concurrent severe/unstable systemic disease\n* No infection\n* No circumstances that would preclude study participation (e.g., alcoholism or substance abuse)\n* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* More than 1 year since prior trastuzumab\n* No concurrent prophylactic growth factors\n\nChemotherapy\n\n* More than 1 year since prior paclitaxel\n* More than 4 weeks since other prior chemotherapy\n\nEndocrine therapy\n\n* More than 1 day since prior hormonal therapy\n* More than 2 days since prior high-dose chronic steroids\n* More than 2 days since prior ethinyl estradiol\n* No concurrent high-dose chronic steroids\n* No concurrent ethinyl estradiol\n\nRadiotherapy\n\n* More than 4 weeks since prior radiotherapy\n\nSurgery\n\n* Not specified\n\nOther\n\n* More than 2 days since prior administration of and no concurrent CYP3A4 inducers or inhibitors, including any of the following:\n\n  * Gestodene\n  * Itraconazole\n  * Ketoconazole\n  * Cimetidine\n  * Erythromycin\n  * Carbamazepine\n  * Phenobarbital\n  * Phenytoin\n  * Rifampin\n  * Sulfinpyrazone\n* No concurrent grapefruit juice\n* No other concurrent anticancer agents\n* No other concurrent investigational therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}